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SUMMARY
Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated by the 
biallelic loss of the RB1 gene. To identify the mutations that cooperate with RB1 loss, we 
performed whole-genome sequencing of retinoblastomas. The overall mutational rate was very 
low; RB1 was the only known cancer gene mutated. We then evaluated RB1’s role in genome 
stability and considered nongenetic mechanisms of cancer pathway deregulation. Here we show 
that the retinoblastoma genome is stable, but multiple cancer pathways can be epigenetically 
deregulated. For example, the proto-oncogene SYK is upregulated in retinoblastoma and is 
required for tumor cell survival. Targeting SYK with a small-molecule inhibitor induced 
retinoblastoma tumor cell death in vitro and in vivo. Thus, RB1 inactivation may allow 
preneoplastic cells to acquire multiple hallmarks of cancer through epigenetic mechanisms, 
resulting directly or indirectly from RB1 loss. These data provide novel targets for 
chemotherapeutic interventions of retinoblastoma.
Retinoblastoma is a rare childhood cancer of the retina that can develop in a sporadic or a 
heritable form and is fatal if untreated. When the RB1 gene was cloned, it was found to 
undergo biallelic inactivation in virtually all retinoblastoma tumors1. Since then, hundreds 
of genetic lesions have been identified in human cancer. These genetic lesions can be 
grouped based on the signaling pathways they affect that have direct or indirect mechanistic 
links to many of the common cellular properties or “hallmarks” of cancer. Thus, the rate of 
cancer progression is related to the kinetics of acquisition of multiple genetic lesions and/or 
epigenetic changes that ultimately lead to activation of growth-signaling pathways, evasion 
of cell death and senescence, acquisition of limitless replicative potential, sustained 
angiogenesis, and local tissue invasion and metastasis2.
RB1 inactivation confers limitless replicative potential to retinoblasts and it is rate limiting 
for retinoblastoma tumorigenesis3. However, the mechanisms that enable retinoblastoma 
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cells to acquire the additional hallmarks of cancer remain unknown. Evidence from 
molecular, cellular, and cytogenetic studies suggest that the RB1 protein is required for 
maintaining chromosomal stability4,5, and its loss leads to chromosome instability (CIN) in 
cells maintained in culture. These data raise the possibility that RB1 inactivation may 
underlie the rapid acquisition of cooperating mutations in key cancer pathways through CIN. 
Alternatively, epigenetic changes may play a more dominant role in cooperating with the 
loss of RB1 retinoblastoma tumorigenesis. RB1 has been implicated in regulating most 
major epigenetic processes, including miRNA regulation, DNA methylation, histone 
modification, and ATP-dependent chromatin reorganization6–10. Thus, inactivation of RB1 
in retinoblasts may lead to the rapid epigenetic deregulation of cancer genes that contribute 
to the essential cellular properties of retinoblastoma.
In this study, we characterized the genetic and epigenetic landscapes of retinoblastoma and 
explore the role of RB1 in regulating genomic stability. Whole-genome sequencing (WGS) 
of 4 retinoblastomas and their paired germline DNA samples showed no genetic lesions in 
known tumor suppressor genes or oncogenes, other than RB1. More importantly, an 
orthotopic xenograft derived from 1 of the primary tumors showed no evidence of clonal 
variation or new coding-region mutations. This finding suggests that retinoblastoma’s 
genome is more stable than previously believed.
Unlike the genetic landscape of retinoblastoma, the epigenetic profile shows profound 
changes compared to that observed in normal retinoblasts. One of the most striking results 
was the induction of the expression of the proto-oncogene SPLEEN TYROSINE KINASE 
(SYK) in human retinoblastoma. SYK is required for tumor cell survival, and inhibition of 
SYK with a small-molecule inhibitor caused the degradation of MCL1 and caspase-
mediated cell death in retinoblastoma cells in culture and in vivo. These findings highlight 
how comprehensive genetic and epigenetic analyses of tumors can be integrated and lead to 
the discovery of promising new therapeutic approaches and shed light on the mechanisms 
underlying the rapid progression of retinoblastoma following RB1 inactivation.
Retinoblastoma Whole-Genome Sequencing
We performed WGS analysis on 4 primary human retinoblastoma samples (Section S1 and 
Table S1) and from matched normal tissue. Local tumor cell invasion but not metastasis was 
evident in each patient (Fig. 1a–c and Fig. S1). We generated an orthotopic xenograft, 
SJRB001X, of the primary tumor SJRB001 by inoculating primary tumor cells into the 
vitreous of the eyes of immunocompromised mice (Section S2). SJRB001X exhibited 
molecular, genetic and histopathologic features similar to SJRB001 (Fig. 1d–f, Figs. S2–4, 
Tables S2–4 and Section S3).
Using a paired-end sequencing approach, we generated 1,040.9 Gb of sequence data for the 
samples described; 956.8 Gb (92%) were successfully mapped to the NCBI 36.1 reference 
genome (Section S4, Table S5). The average genome coverage was 28.9×, and the average 
exon coverage was 23.8× with 98.4% of SNPs detected across all 9 genomes showing 
concordance with their corresponding SNP array genotype calls at the same genomic 
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positions (Table S5). To provide additional sequence coverage, we performed transcriptome 
sequencing of SJRB001-4 (Section S5, Table S6).
We identified 668 validated somatic sequence mutations and 40 structural variations (SVs) 
across the 4 cases (Table 1). These included 23 tier-1 mutations in genes, 35 tier-2 mutations 
in evolutionarily conserved regions of the genome (Section S6), 309 tier-3 mutations in 
nonrepetitive regions of the genome that are not part of tiers 1 and 2; and 301 tier-4 
mutations in repetitive sequences in the genome (Table 1 and Table S7). The average 
number of sequence mutations was 167 per case (range, 56–258), with only 3.25 mutations 
per case (range, 0–5) resulting in amino acid changes (Table 1). The estimated mean 
mutation rate was 6.7×10−7 per base (range 1.03×10−7–2.17×10−8), which is 15-fold less 
than that in adult tumors analyzed by WGS, except for AML11. The predominant changes 
were C>A and G>T transversions (Fig. S5), which is consistent with the possibility that 
some of the transversions result from production of 8-Oxoguanine during oxidative stress. 
SJRB002 had no somatic sequence variations that resulted in amino acid changes; the only 
SVs were the loss of heterozygosity (LOH) at the RB1 locus and a gain of chromosome 6p. 
This suggests that very few genetic lesions are required for retinoblastoma progression after 
RB1 inactivation.
RB1 gene inactivation in retinoblastoma
Both RB1 alleles were inactivated in each sample (Figs. S6, S7). SJRB002 and SJRB003 had 
mutations in RB1 combined with copy number–neutral LOH, and SJRB001 and SJRB004 
had somatic sequence mutations combined with RB1-promoter hypermethylation (Figs. S6–
8). Deep-sequence analysis of the germline sample from SJRB002 revealed that about 10% 
of reads contained the R445 nonsense mutation, suggesting the presence of germline 
chimerism for the RB1 mutation (Fig. S6). Combining the WGS data with SNP array data of 
an additional 42 samples, we found that tumors from patients with lower regional nucleotide 
diversity were much less likely to undergo LOH at the RB1 locus (Tables S8, S9, Section 
S7). These data show for the first time a significant association (p=8×10−8, Fisher’s exact 
test) between a germline genetic variation and mechanism of biallelic RB1 inactivation in 
retinoblastoma.
Recurrent lesions in retinoblastoma
To determine whether any of the 11 genes with somatic mutations that caused amino acid 
changes or a frameshift in the coding region (Table 1, Fig. 2a,b, Figs. S9, S10, Section S8, 
Table S10), were recurrently mutated in retinoblastoma, we sequenced all exons from the 11 
genes in our recurrent screening cohort of 42 retinoblastomas (Section S4). Only BCOR was 
recurrently mutated in of retinoblastoma (6/46, 13%). Five of the samples had BCOR 
mutations that resulted in premature truncation of the encoded protein, and 1 sample had a 
focal gene deletion (Fig. 2c, Table S11, Fig. S11).
We also used the WGS data to identify somatic SVs including whole-chromosome gains and 
losses, focal deletions (DEL), insertions (INS), inversions (INV), intrachromosomal 
rearrangements (ITX), interchromosomal rearrangements (CTX), and regions of LOH (Fig. 
2a–c, Section S9, Table S12, Fig. S12). The average number of SVs was 10 per case (range, 
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0–24) (Table 1). SJRB001 had 4 SVs (2 DEL and 2 INS) including a gain of a region of 
chromosome 2 spanning MYCN (Table S12) and the only chromosomal lesion in SJRB002 
was a gain of 6p, which occurs in about 40% of human retinoblastomas12 (Fig. 2b). Only a 
few genomic regions were affected by the SVs in SJRB003 and SJRB004 (Figs. S10, S13, 
S14, Table S12).
Orthotopic retinoblastoma xenograft
The genomic landscape of the orthotopic xenograft was remarkably similar to that of the 
primary tumor, despite continuous growth and multiple passages in vivo over 9 months (Fig. 
2, Table 1). All of the single-nucleotide variants (SNVs) and SVs detected in SJRB001 were 
retained in SJRB001X. Only 67 new SNVs and 4 SVs were identified in the xenograft, and 
none targeted annotated genes (Fig. 2, Table 1). Moreover, each mutation was identified at a 
subclonal level (range, 20%–30%) and the mutant allele frequency for the Tier1-4 lesions in 
SJRB001 was retained in SJRB001X (Supplementary Fig. 15). This result was surprising 
because several studies in mice and cell cultures have linked RB1 inactivation to defects in 
chromosome segregation that result in aneuploidy 4,5,13–15 and CIN4. We measured the 
distance between sister chromatids, between kinetochores, and the proportion of lagging 
chromatids in 2 RB1-deficient human retinoblastoma orthotopic xenografts (SJRB001X and 
SJRB002X)16. Consistent with results from RB1-deficient RPE cells4, the distances between 
sister chromatids and kinetochores were increased, and there was evidence of lagging 
chromosomes (Figs. S16, S17). However, less variation in ploidy was observed during 
spectral karyotype (SKY) analysis of SJRB001X and SJRB002X that was more consistent 
with the ploidy of wild-type cells (Fig. 3a,b, Table S13). Moreover, CNVs were much lower 
in our cohort of 46 retinoblastomas than in tumors with known genome instability such as 
ovarian cancer (Fig. 3c). Together, the cytogenetic data and WGS data suggest that the 
genome is stable and newly acquired lesions do not provide a selective growth advantage 
and are thus likely passenger mutations.
Identifying deregulated cancer pathways
There are many examples over the past several decades of epigenomic changes such as 
DNA methylation contributing to tumorigenesis17–19. Indeed, a recent study demonstrated 
changes in DNA methylation in Wilm’s tumors20 which, tend to have stable genomes like 
retinoblastomas. To explore whether epigenetic deregulation of genes or pathways promotes 
tumorigenesis in retinoblastoma, we carried out an integrative analysis of chromatin 
immunoprecipitation (ChIP) data, DNA-methylation data and gene expression data using 
order statistics. The SJRB001X sample was used for ChIP assay (Figs. S18–20), and 
primary tumor and xenograft samples were used for both DNA-methylation and gene 
expression assays. In all three analyses, experimental results in RB tumors were compared to 
those from human fetal retinae. A total of 104 genes, including 15 known cancer genes (Fig. 
4a and Tables S14, S15), were found to have significant difference between RB tumors and 
human fetal retina, indicating that several key cancer genes were epigenetically deregulated.
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SYK is a novel therapeutic target
SYK is the 5th most significant gene identified by the integrative analysis and the only up-
regulated kinase gene (Table S15 and Fig. 4a). SYK is expressed throughout the 
hematopoietic system, regulates immunomodulatory signaling, and has been implicated in 
several hematologic malignancies21–24. Small-molecule inhibitors of SYK have been 
developed to treat autoimmune disorders25, and 2 of those agents, BAY61-3606 and R406, 
have shown efficacy in preclinical leukemia studies26–28.
ChIP-on-chip analysis showed increased activating histone modifications (H3K4me3 and 
K3K9/14Ac) at SYK’s promoter, and the repressive histone marker (H3k9me3) was 
unchanged. RNA polymerase II binding to the SYK promoter was also increased (Fig. 4b, 
Tables S14, S15). These ChIP-on-chip results were validated in independent samples by 
real-time RT-PCR analysis (Fig. 4c), and we confirmed the increase in SYK gene expression 
(Fig. 4d). SYK protein levels were higher in human retinoblastoma orthotopic xenografts 
and cell lines than in human fetal retinae (Fig. 4e). To determine whether SYK is expressed 
in primary human retinoblastomas, we performed immunohistochemistry on a 
retinoblastoma tissue microarray (TMA) or whole eye sections. In total, 100% (82/82) 
showed very strong expression (3+) of SYK in all tumor cells; SYK was not expressed in 
normal retina (Fig. 4f). SYK’s kinase activity is regulated through autophosphorylation at 
the Tyr525/526 residues within its catalytic domain. These sites were phosphorylated in 
retinoblastoma cells, and this phosphorylation was reversed by BAY 61-3606 or R406 
exposure (Fig. 4g and data not shown).
To determine whether SYK expression is required for retinoblastoma growth, survival, or 
both, we generated an shRNA to SYK and cloned it into the lentiviral vector Lenti-SYK-9. 
Lenti-SYK-9 efficiently knocked-down SYK in retinoblastoma cell lines (Fig. S21) and 
dramatically increased apoptosis in retinoblastoma cells (Fig. 4h, Fig. S21). Similar results 
were obtained in vivo using SJRB001X (data not shown). We used an empty lentiviral 
vector and a lentiviral vector encoding an SYK shRNA that less effectively reduced SYK 
expression (Lenti-SYK-6) as controls. Cell lines that do not express SYK (BJ, 293T, and 
uninduced Jurkat cells) were used as controls and the Lenti-SYK-9 lentivirus had no effect 
on the growth or apoptosis of the control cells.
We exposed retinoblastoma cell lines that express high levels of SYK (Weri1 and RB355) to 
various concentrations of the SYK inhibitors BAY 61-3606 or R406 for 72 hours and then 
measured cell viability. Jurkat (uninduced) and 293T cells were used as negative controls. 
Weri1 and RB355 cells were sensitive to both SYK inhibitors, but the Jurkat and 293T cells 
were unaffected (Fig. 5a). Transmission electron microscopy of retinoblastoma cells treated 
with the SYK inhibitors showed morphologic features consistent with cell death and 
mitochondrial defects (Fig. S22); this was confirmed by scoring the proportion of activated 
caspase-3+ cells (Fig. 5b, c, Fig. S22). Jurkat cells showed no increase in activated 
caspase-3+ cells after treatment with 10 µM R406 or BAY 61-3606 (data not shown).
The proportions of cells from each line that incorporated EdU were similar, suggesting that 
retinoblastoma’s cell cycle is not affected by SYK inhibition (Fig. 5d, e, Fig. S22). The 
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effects of targeting SYK were partially rescued by the pan-caspase inhibitor Q-VD-OPH 
(Fig. S22). Less MitoTracker Red accumulated in retinoblastoma cells exposed to the SYK 
inhibitors (Fig. S22), yet treatment of Jurkat cells with either inhibitor had no effect on 
MitoTracker Red accumulation (data not shown). Inhibiting SYK in B-CLL cells reduced 
their autophosphorylation of SYK and destabilized MCL126,29, the only antiapoptotic 
member of the BCL-2 family that is upregulated in retinoblastoma (data not shown). Both 
inhibitors reduced autophosphorylation of SYK on Y525/526 (Fig. 4g) and reduced MCL1 
expression coincident with apoptosis (Fig. 5f).
We tested the efficacy of BAY61-3606 in vivo on our SJRB001X model30. The 
chemotherapy regimen consisted of a single subconjunctival dose of BAY 61–3606 on Day 
1 and daily doses of topotecan (TPT) on Days 1–5 until either 6 courses (21 days per course) 
were administered, or the tumor progressed and surgical enucleation was required (Fig. 
5g,h). BAY 61-3606+TPT significantly improved outcome (p=0.003) (Fig. 5i), and its 
efficacy was correlated with an increase in activated caspase-3+ cells in the treated eyes 
(Fig. 5j). Previous studies using this model have shown that TPT combined with 
subconjunctival carboplatin had no effect on tumor response or outcome 30, so the 
improvement seen here can be attributed to targeting SYK. MCL1 expression was also 
reduced in the treated eyes, which is consistent with increased apoptosis and targeting SYK 
in vivo (Fig. 5k). Together, these results suggest that SYK is a promising new target for 
treating retinoblastoma.
DISCUSSION
It has been suggested that biallelic loss of RB1 directly causes genomic instability, which in 
turn contributes to the rapid development of overt retinoblastoma. Our data failed to support 
this hypothesis. The mutational rate and number of SVs per case that we assessed were 
among the lowest reported in human cancer. Moreover, the only non-silent mutation in 
SJRB002 was in RB1, and no SVs were detected. The minimal increase in passenger 
mutations in SJRB001X cells, despite prolonged passage, was also consistent with a 
relatively stable genome. These results support those from previous studies showing that 
retinoblastoma karyotypes are stable in vitro and in vivo31,32. Our data suggest that genomic 
instability is neither a hallmark of retinoblastoma nor sufficient to explain how 
retinoblastomas progress so rapidly.
We propose that epigenetic mechanisms contribute to retinoblastoma tumorigenesis. We 
identified several known oncogenes and tumor-suppressor genes with histone modifications 
and altered DNA methylation that correlated with changes in gene expression. Our key 
discovery was that SYK is important in retinoblastoma. Retinal progenitor cells and retinal 
neurons express little to no SYK, and SYK has no known function in the developing visual 
system. Moreover, no recurrent genetic lesions in SYK are associated with retinoblastoma to 
suggest that this gene drives tumorigenesis. Only by integrating epigenetic and gene 
expression analyses, did we identify SYK as an important oncogene in retinoblastoma. This 
is important not only for expanding our understanding of the biology of retinoblastoma but 
also for advancing immediate therapeutic options that were not previously considered such 
as BAY 61-3606 or R406. This study highlights the value of integrating WGS analyses of 
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the genetic and epigenetic features of tumor genomes toward finding a cure for cancers such 
as retinoblastoma.
METHODS SUMMARY
Full details of sample acquisition, molecular and biochemical procedures, informatics and 
whole genome sequencing and animal and drug studies are provided in the Supplementary 
Information. The SJCRH IRB approved experiments involving human subjects and 
informed consent was obtained from all subjects. For animal studies, all experiments were 
performed in accordance with federal guidelines and regulations. The SJCRH IACUC 
approved all animal experiments. The dbGaP accession assigned to this study is 
phs000352.v1.p1. Lentiviral vectors (GIPZ with Lenti-SYK-9 #V3LHS-366147 and Lenti-
SYK-6 #V3LHS-366143) encoding shRNAs to SYK were purchased from OpenBiosystems, 
Inc.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterization of retinoblastomas samples
a–c, Representative retinoblastoma tumor section(SJRB001) stained with hematoxylin and 
eosin (H&E) showing choroidal and optic nerve invasion (arrow). d–f, H&E-stained section 
of the SJRB001X orthotopic xenograft with choroidal (e) and optic nerve (f) invasion 
(arrows). Abbreviations: AC, anterior chamber; ON, optic nerve; Sc, sclera. Scale bars: 25 
µm.
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Figure 2. Genomic profiles of SJRB001-2 and SJRB001X
a,b, CIRCOS plots of genetic alterations in 2 retinoblastomas and the matched orthotopic 
xenograft. Loss of heterozygosity (orange), amplifications (red), and deletions (blue) are 
shown. Interchromosomal translocations (green lines) and intrachromosomal translocations 
(purple lines) are indicated. Sequence mutations in Refseq genes included silent single 
nucleotide variants (SNVs, green), missense SNVs (brown), nonsense SNVs (dark blue), 
splice-site mutations (pink), and insertion/deletion mutations (indels, red). c) BCOR 
mutations identified in the recurrency cohort.
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Figure 3. Analysis of aneuploidy and CIN in retinoblastoma
a, Chromosomal missegregation of SJRB001X cells after at least 21 rounds of cell division 
is plotted in red. b, Representative SKY image of SJRB001X after the third passage in mice. 
c, Alterations in the 46 Rb cases (Rb) compared to 153 high-grade serous ovarian cancer 
(Ov) from TGCA. The median chromosomal lesions for retinoblastoma (Rb) was 1.5% and 
27.7% for ovarian cancer (Ov).
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Figure 4. SYK Is Expressed in Retinoblastoma and Is Required for Survival
a, Whole-genome view of the gene ranks based on integrating ChIP-on-chip, methylation, 
and gene expression results. Y-axis is –log(p), where p is a p-value of Q-statistic corrected 
for multiple testing. Significantly (FDR ≤10%) downregulated (green) or upregulated (red) 
genes are shown. b, c, ChIP validation of histone markers of the SYK promoter including 
quantification by quantitative PCR (qPCR) with TaqMan probes. Each bar is the mean and 
standard deviation of triplicate samples. d, SYK gene expression measured by qPCR in fetal 
week 20 retina (fetal), primary retinoblastoma (tumor), orthotopic xenografts (SJRB001X 
and SJRB002X) and cell lines. Each bar is the mean and standard deviation of duplicate 
samples normalized to GPI1 expression. e, Immunoblot of SYK (green) and actin (red) in 
orthotopic xenografts, human fetal retina, and representative cell lines; black and white 
representation of the SYK immunoblot is in the lower panel. f, H&E (purple) and anti-SYK 
(brown) immunohistochemistry of retinoblastoma tissue. g, Immunoprecipitation analysis of 
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SYK and pSYK Y525/526 from Weri1 retinoblastoma cells. h, Viability was measured in 
triplicate cultures 72 hours after infection of retinoblastoma cells with a lentivirus vector 
expressing either a control lentivirus or an shRNA against SYK. Scale bars: 10 µm.
Zhang et al. Page 15
Nature. Author manuscript; available in PMC 2012 July 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 5. Retinoblastoma Cells are Sensitive to SYK Inhibitors
a, Dose response for SYK inhibitors R406 (red) and BAY 61-3606 (black) in RB355 
retinoblastoma cells and a negative control (Jurkat). Each data point is the mean and 
standard deviation of triplicate samples. b–e Immunofluorescence of activated caspase 3 or 
EdU(red) before and after treatment of RB355 cells with R406 or BAY 61–3606. A total of 
250 cells were scored in duplicate for each sample and each treatment condition to derive 
the mean and standard deviation. Nuclei were stained with DAPI (blue). f, Treatment of 
stimulated Jurkat or RB355 cells with 5 µM BAY 61–3606 for 24 hours reduced MCL1 
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expression. g, Schematic of the treatment schedule for mice with SJRB001X tumors. h, 
Representative MR images of a mouse whose tumor responded after 4 courses of treatment 
with BAY 61–3606 (left) and another whose disease progressed during treatment (right). i, 
Survival curves show that BAY 61–3606+TPT treatment improved outcome. j, 
Immunostaining for activated caspase 3 (arrows) in untreated or BAY 61–3606–treated 
eyes. k, untreated or BAY 61-3606–treated eyes. k, Immunoblot showing reduced MCL1 
protein after BAY 61–3606 or BAY 61–3606+TPT treatment. Scale bars b, d: 5 µm; j: 10 
µm.
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